9 results about "Bioabsorbable polymer" patented technology

The present disclosure provides a method for preventing blood coagulation, comprising administering an effective amount of ginsenoside compound K (CK) to a subject in need thereof. The present disclosure also provides a use of ginsenoside compound K (CK) in the manufacture of a medicament for preventing blood coagulation. The present disclosure further provides a drug-eluting percutaneous coronary intervention (PCI) device comprising a vascular implant, the surface of which is coated with a first layer comprising ginsenoside compound K (CK) and a first bioabsorbable polymer, the first bioabsorbable polymer comprising poly-L-lactic acid (PLLA) and poly(L-lactide-co-ε-caprolactone) (PLCL) in a mass ratio of 60%-80%:20%-40%.

Provided is an adhesion prevention film that sufficiently swells upon contact with moisture and is less prone to breaking. This adhesion prevention film contains a bioabsorbable polymer compound. The adhesion prevention film has a thickness of 10-500 µm, and a swelling ratio of 200-500 vol% after 15-minute immersion in phosphate buffer at pH 6.0. In the case where 1H-NMR measurement of the film is performed, using a sample solution prepared by adding the film and 1.2 mg of pyrazine to 1.1 mL of deuterated trifluoroacetic acid, with the resonance peak of pyrazine as a standard substance referenced to 9.45 ppm, when the integral value of the maximum resonance peak measured in the range of 9.4-9.5 ppm is defined as A and the integral value of the maximum resonance peak measured in the range of 5.0-5.2 ppm is defined as B, B / A is 0.10 or less.

To provide a depot for treating post-operative pain via sustained controlled release of a therapeutic agent.SOLUTION: In some embodiments, the depot may comprise a therapeutic region comprising an analgesic agent and a control region comprising a bioabsorbable polymer and a release agent admixed with the polymer. The release agent may be configured to dissolve when the depot is placed invivo to form a diffusion aperture in the control region. The depot may be configured to be implanted at a treatment site invivo and release the therapeutic agent at the treatment site for 3 days or more while implanted.SELECTED DRAWING: None

Long-acting resorbable subcutaneous implant with extended release of pre-concentrated pharmacologically active substance in polymer for treatment of chronic adrenal insufficiency. The implant is inserted subcutaneously and has continuous release of the active ingredient for an extended period of time. The implant may have in its constitution only hydrocortisone but is preferably formed by hydrocortisone particles homogeneously dispersed in a bio erodible and bioabsorbable polymer matrix. Such a polymer matrix may be formed of a polymer or a polymer blend. The release of the drug in this system occurs through diffusion, at a relatively constant rate, and it is possible to change the rate of release of the drug through the thickness or material of this membrane.

The invention relates to a nerve regeneration inducing material. The present invention provides a non-tubular nerve regeneration inducing material for regenerating a nerve injury part, the material comprising: (A) a crosslinked body obtained by covalently crosslinking a bioabsorbable polysaccharide having a carboxyl group in the molecule with a low endotoxin with at least one crosslinking agent selected from the group consisting of compounds represented by general formula (I) and salts thereof; and (B) a bioabsorbable polymer. R1 HN-(CH2) n-NHR2 (I) [In the formula, R1 and R2 each independently represent a hydrogen atom or a group represented by the formula-COCH (NH2)-(CH2) 4-NH2, and n represents an integer of 2-18]. As a result, a medical material capable of inducing regeneration of a nerve injury part is provided.

Stapling assemblies for use with surgical staplers are provided. In one exemplary embodiment, the stapling assembly includes a cartridge having a plurality of staples disposed therein and a non-fibrous adjunct formed of at least one fused bioabsorbable polymer and configured to be releasably retained on the cartridge. An adjunct system for use with surgical staplers is also provided. Surgical end effectors for use with the stapling assemblies are also provided. Methods for manufacturing and using the stapling assemblies are also provided.

Stapling assemblies for use with surgical staplers are provided. In one exemplary embodiment, the stapling assembly includes a cartridge (4502) having a plurality of staples disposed therein and a non-fibrous adjunct (4500) formed from at least one fused bioabsorbable polymer and configured to be releasably retained on the cartridge. An adjunct system for use with a surgical stapler is also provided. Surgical end effectors using the stapling assembly are also provided. Methods for manufacturing and using the stapling assembly are also provided.

To provide an implantable polymer depot for controlled release of therapeutic agents. [Solution] This technology relates to the assembly of a depot for controlled sustained release of a therapeutic agent. The assembly may include a depot having a therapeutic region containing the therapeutic agent, and a control region containing a bioabsorbable polymer and a release agent mixed with the polymer. The release agent may be configured to form a diffusion opening in the control region when the depot is placed in vivo. The depot may be implanted in vivo at the treatment site and may be configured to release the therapeutic agent to the treatment site for three days or more while implanted.

Provided is an adhesion-preventive film which is hardly broken when folded or rolled. The adhesion-preventive film contains a bioabsorbable polymer compound, has a thickness of 10-500 μm, and has a folding endurance of 10-2,000 times as measured by an MIT tester.